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Ovarian cancer continues to be a major cause of morbidity and mortality in women. Antiangiogenic treatments have emerged as a
promising strategy to treat ovarian cancer. This article reviews the rationale supporting the use of antiangiogenic treatments in ovarian
cancer, the clinical development of this group of drugs and the toxicities specific to this modality of treatment.
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Ovarian cancer is the fourth most common cause of cancer death
in women. Worldwide, there are more than 190000 new cases of
ovarian cancer each year, accounting for around 4% of all cancers
diagnosed in women. Incidence rates vary considerably, with the
highest rates in the United States and Northern Europe and the
lowest rates in Africa and Asia.
The majority of patients with ovarian cancer present late with
advanced disease (FIGO stage III/IV) and in this group of patients,
despite multimodality treatment with surgical debulking followed
by platinum–taxane combination chemotherapy, median survival
is only 3 years.
New treatment approaches are therefore urgently required
to improve outcome in this disease and one promising
strategy to have emerged has been the study of angiogenesis in
ovarian cancer and the role of modulators of angiogenesis in its
treatment.
Angiogenesis is the process of new blood vessel development
and is crucial for the growth of tumours beyond 100–200mmi n
diameter as diffusion of nutrients and oxygen from nearby
capillaries is inadequate beyond this point to sustain cell function
(Folkman et al, 1989). Early in tumorogenesis, an ‘angiogenic
switch’ is flipped whereby the previously closely maintained
physiological balance that keeps the adult vasculature in a
generally quiescent state is tipped towards angiogenesis with
upregulation of pro-angiogenic growth factors such as VEGF
(vascular endothelial growth factor), FGF-2 (fibroblast growth
factor-2) and their receptors and downregulation of antiangiogenic
factors like thrombospondin-1 and angiostatin (Hanahan and
Folkman, 1996). Although sprouting angiogenesis is clearly the
most important mechanism for tumour vascularisation, several
other pathways have been identified including vessel co-option,
vasculogenic mimicry and intussusceptive angiogenesis (for
further information see Hillen and Griffioen, 2007).
The VEGF family of growth factors and its receptors constitute
the most important signalling pathways in tumour angiogenesis
and have been well characterised by research over the last two
decades. Vascular endothelial growth factor-A was initially
identified as a vascular permeability factor in 1983 and later
characterised as an endothelial-specific mitogen by Ferrara and
Henzel (1989). Subsequently, seven family members have been
identified – VEGF-A to -E and placental growth factor (PlGF)-1
and -2. They signal through three tyrosine kinase receptors,
VEGFR-1 to –3, to which the growth factors bind, leading to the
dimerisation and activation of downstream signalling cascades.
Both VEGFR-1 and -2 can promote angiogenesis and VEGFR-3
stimulation leads to lymphangiogenesis. Although VEGFR-1 has a
10-fold higher binding affinity for VEGF-A, its activation has less
of an impact on the activation of intracellular signalling
intermediates than VEGFR-2 (Waltenberger et al, 1994). A degree
of specificity has been shown for growth factor-receptor binding,
VEGF-B and PlGF-1 and -2 bind to VEGFR-1, whereas VEGF-A
interacts with both VEGFR-1 and -2. Vascular endothelial growth
factor-C and -D specifically bind to VEGFR-3. There is a general
consensus, however, that VEGFR-2 is the dominant receptor in
mediating the pro-angiogenic functions of VEGF-A and this
pathway has been prioritised for the development of antiangio-
genic therapies.
ANGIOGENESIS IN OVARIAN PHYSIOLOGY
Each female reproductive cycle involves rapid increases in
ovarian and endometrial tissue mass and vascularity with
subsequent regression in non-fertile cycles. These changes are
promoted by co-ordinated interactions between steroid
hormones and angiogenic factors. At the start of an ovulatory
cycle, a number of ovarian follicles start the step by step
process of maturation with the subsequent selection of one or
two dominant follicles, which are characteristically of higher
vascularity (Ramakrishnan et al, 2005). These dominant follicles
subsequently release ova and afterwards turn into a temporary
endocrine tissue (corpus luteum) synthesising the steroid
hormones required for endometrial development. Angiogenesis
is the key to follicular development and the degree of vascularity
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www.bjcancer.comcontinues to increase during the luteal phase to supply nutrients and
steroid precursors and allow the export of active steroid hormones
to the endometrium. New vessel formation and development is
therefore critical for the whole reproductive cycle, and the role of
vascular growth factors involved in the regulation of this process is
shown by their cyclical change corresponding to the various stages
of the menstrual cycle. Intrafollicular levels of the VEGF family of
proteins, in particular VEGF-A, increase during the initial part of
the ovulatory cycle, with peak concentrations detected just before
the start of the luteal phase. Treatment with VEGF inhibitors,
including VEGF Trap, a soluble decoy receptor composed of parts of
the growth factor-binding domains of VEGFR-1 and -2 fused to the
Fc region of human IgG1 during the follicular phase, suppresses
ovulation (Fraser et al,2 0 0 5 ) .
The subsequent regression of the vasculature during follicular
atresia is triggered by increases in the levels of angiogenic
inhibitors, in particular upregulation of Ang-2, towards the end
of the luteal phase (Ramakrishnan et al, 2005).
ANGIOGENESIS IN OVARIAN CANCER
Although microvascular density, a commonly used surrogate
marker for tumour angiogenic potential, has not been shown
to correlate convincingly with prognosis in ovarian cancer
(Sonmezer et al, 2004; Gadducci et al, 2006), both pre-clinical
and clinical studies investigating the VEGF family and its
downstream signalling pathways have indicated the key
importance of angiogenesis in the pathophysiology of ovarian
cancer.
In animal models of ovarian cancer, it has been shown that
VEGF blockade inhibits ascites formation and slows tumour
growth (Byrne et al, 2003). Several retrospective clinical studies in
ovarian cancer have also demonstrated that intratumoral VEGF
and VEGFR-2 expression and the carriage of VEGF gene
polymorphisms associated with an increased VEGF excretion are
independent poor prognostic factors (Shen et al, 2000; Goodheart
et al, 2005; Hefler et al, 2007).
Neuropilin-1 and -2 are cell surface proteins that bind to the
commonest isoform of VEGF-A (VEGF-165) and may act as
co-receptors to enhance VEGF signalling through VEGFR-1.
Neuropilin expression is increased in ovarian carcinomas (Ferrara
and Kerbel, 2005; Osada et al, 2006).
The intratumoral vasculature tends to be structurally and
functionally abnormal with tortuous, leaky, dilated and immature
vessels with poor flow. The endothelial cells in these newly formed
vessels are more dependent on VEGF as a mitogen for survival
than in mature vasculature elsewhere in the body (Kamba et al,
2006). It has been suggested that VEGF inhibition remodels and
‘normalises’ the intratumoral vasculature, leading to a better
delivery of oxygen and concomitant chemotherapy to the normally
hypoxic and acidic tumour milieu (Jain, 2001).
The inhibition of angiogenesis was initially proposed as a
therapeutic target that may avoid the development of drug
resistance. The genetic instability of tumour cells promotes the
emergence of drug-resistant clones, whereas traditionally, this was
considered unlikely to occur in ‘host’ endothelial cells that were
thought to possess a stable genome. However, it is clear from the
clinical studies discussed below that resistance to antiangiogenic
treatment strategies is common and recent evidences suggest that
in addition to morphological differences, tumour endothelial cells
have distinct gene expression profiles (Seaman et al, 2007)
compared with normal endothelium and can also be cytogeneti-
cally abnormal (Hida et al, 2004).
It is also now clear that VEGF receptors can be expressed
and functional on cancer cells, indicating that anti-VEGF
treatment strategies may have direct antitumour effects (Wedam
et al, 2006).
TARGETING THE VEGF PATHWAY IN OVARIAN
CANCER
Given the apparent key importance of the VEGF signalling
pathway in normal ovarian physiology and in ovarian cancer,
results of clinical trials with agents targeting this pathway have
been eagerly anticipated.
Bevacizumab, a humanised monoclonal antibody directed
against VEGF, was the first antiangiogenic agent to be licensed
in the treatment of cancer and has improved survival when
administered in combination with chemotherapy in a broad
range of epithelial malignancies (Hurwitz et al, 2004; Sandler et al,
2006; Miller et al, 2007). Although response rates to bevacizumab
alone are very low in other tumour types, it has shown
exciting single-agent activity at a dose of 15mgkg
 1 every 3
weeks in two phase II trials in patients with recurrent ovarian
cancer, the majority of whom had platinum-resistant disease
(Burger et al, 2007; Cannistra et al, 2007). Response rates of 16 and
21% were recorded with median progression-free survival of
4.4 and 4.7 months, significantly higher than those seen in
previous phase II studies in this patient population. It is worth
noting that however, the tolerability of bevacizumab differed
in the two studies as discussed below. Bevacizumab has also been
combined safely with carboplatin–paclitaxel chemotherapy in the
first-line management of ovarian cancer (Penson et al, 2006),
and this combination is currently being compared with
chemotherapy alone in two large phase III trials (GOG-218
and ICON7). ICON7 is a two-armed trial comparing
carboplatin and paclitaxel (six cycles) against carbopla-
tinþpaclitaxelþbevacizumab (7.5mgkg
 1, every 3 weeks) for
six cycles followed by 12 cycles of maintenance bevacizumab.
GOG-218 is a three-arm placebo-controlled study – all patients
receive carboplatin and paclitaxel for six cycles – in the first
experimental arm, patients also receive concurrent and main-
tenance bevacizumab (15mgkg
 1, every 3 weeks) for up to 16
doses, whereas the second experimental arm receives only
concurrent bevacizumab followed by placebo maintenance.
The soluble decoy receptor, aflibercept (VEGF Trap), a fusion
protein containing the VEGF-binding domains of both VEGFR-1
and -2 linked through the Fc region of human IgG1, is also under
investigation as a single agent in relapsed platinum-resistant
ovarian cancer with a response rate of 8% and acceptable toxicity
being reported at a pooled interim analysis of a phase II study of
two different dosing regimens (Tew et al, 2007).
Several small molecule tyrosine kinase inhibitors that target
VEGFRs have now been investigated in the phase II setting in
relapsed ovarian cancer and promising results have recently been
presented (summarised in Table 1 and Figure 1). Intriguingly, the
development of effusions was noted in some patients during the
2-week treatment break in sunitinib dosing probably due to the
sudden release of VEGF inhibition, and so a continuous dosing
regimen is now being explored (Biagi et al, 2008). Cediranib
(AZD2171), which targets VEGFR-1, -2 and -3, is now being
tested in platinum-sensitive relapsed ovarian cancer in a
three-arm randomised placebo-controlled phase III trial
in combination with carboplatin–paclitaxel (ICON6). Cediranib
is administered concurrently with chemotherapy in both experi-
mental arms, but is continued in a maintenance phase of up to 18
months duration in one of these (Table 1).
The use of combination anti-VEGF therapy has also been
explored addressing the hypothesis that parallel inhibition at
different points in the signalling pathway may translate into
increased efficacy. A phase I study of sorafenib and bevacizumab
demonstrated durable partial disease responses (4–22þ months)
in 6 of 13 ovarian cancer patients recruited. Toxicity appears
higher than that with single-agent anti-VEGF therapy, with two-
thirds of the patients developing hypertension and 79% incidence
of grade 1–3 hand–foot syndrome (Azad et al, 2008). Enteral
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Eligibility criteria Dose regimen
No. of
patients
% Platinum
resistant Efficacy Reported Gd3/4 toxicities
Cediranib (Matulonis
et al, 2008)
Up to two prior lines
of therapy,
ECOG PS 0/1
45mg o.d. reduced
to 30mg o.d. (toxicity)
29 55 18.5% (response rate) Hypertension (45%), fatigue
(17%), diarrhoea (10%)
Cediranib (Hirte
et al, 2008)
One prior line of therapy,
ECOG PS 0–2
45mg o.d. reduced
to 30mg o.d. (toxicity)
60 57 41% platinum sensitive,
29% resistant (response
and disease stabilisation)
Hypertension (33%),
fatigue (20%)
Sunitinib (Biagi
et al, 2008)
Up to two prior lines
of therapy
50mg o.d. 4 out
of 6 weeks
17 ? 12% (PR), 59% (response/
stabilisation)
Fatigue, hand–foot
syndrome, neutropaenia,
thrombocytopaenia
Sorafenib (Matei
et al, 2008)
Up to two prior lines
of therapy,
GOG PS 0–2
400mg o.d. 73 (59
evaluable
for response)
? 3% (PR), 20% (stable
disease46months)
Rash (17%), metabolic
(15%), gastrointestinal (4%)
Pazopanib (Friedlander
et al, 2007)
Relapsed disease after
complete CA-125 response
to first-line therapy,
ECOG PS 0–1
800mg o.d. 17 26 47% (CA-125 response) Diarrhoea (12%), ALT
elevation (12%)
ALT¼alanine transaminase; ECOG¼Eastern Cooperative Oncology Group; GOG¼Gynecologic Oncology Group; o.d.¼once a day; PR¼partial response;
PS¼performance status.
VEGF-B
PlGF 1 and 2
VEGF-A
VEGF-C
VEGF-D
VEGFR1
NR-1
VEGFR2
VEGFR3
NR-2
VEGF-E
VEGF trap
Soluble VEGFR
Antibody to VEGF
Tyrosine kinase 
inhibitors
AlphaV integrins
Notch receptor
DLL4
NCID
PKC
Antibody to VEGFR
Figure 1 Strategies to inhibit the VEGF signalling pathway. Neuropilins (NRs) can function as co-receptors for vascular endothelial growth factor receptor
(VEGFR). VEGF Trap (decoy receptor), growth factor-binding domains of VEGFR-1 and -2 bound to Fc fragment of IgG, and tyrosine kinase inhibitors (TKIs)
prevent phosphorylation of VEGFR in response to VEGF binding. Delta-like ligand-4 (DLL4) binds to the Notch receptor, which leads to the cleavage of the
Notch intracellular domain (NCID). The cleaved NCID translocates to the nucleus leading to the transcription of notch target genes. Protein kinase C (PKC)
family of kinases are downstream mediators of VEGFR signalling. PlGF¼placental-like growth factor.
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TOXICITY WITH VEGF INHIBITORS
Treatments that interfere with VEGF function are generally well
tolerated although a specific side-effect profile is associated with
this treatment modality.
The most common toxicities are hypertension (grade 3 in
approximately 10% patients), proteinuria (usually grade 1–2),
haemorrhage, arterial and venous thrombotic events, impaired
wound healing and, of particular concern in the initial phase II
bevacizumab trials in ovarian cancer, gastrointestinal perforation.
Although the role of VEGF in normal endothelial homoeostasis
is not well understood, the rapid regression of capillaries in several
different tissues such as pancreatic islets, thyroid, adrenal cortex,
choroid plexus and small intestinal villi is seen within a few days of
starting treatment with VEGF inhibitors in animal models (Kamba
et al, 2006). Loss of fenestration of renal glomerular capillaries also
occurs, which might contribute to hypertension and proteinuria
(Izzedine et al, 2007). Vascular endothelial growth factor also
promotes endothelial nitric oxide production, and the removal of
this stimulus may lead to vasoconstriction and hypertension
(Baffert et al, 2006; Kamba et al, 2006).
Bowel perforation is a feared adverse event associated with
bevacizumab and it was observed at a higher frequency in
colorectal cancer patients receiving concurrent chemotherapy
(1.5% cases compared with 0% of patients receiving chemotherapy
alone) (Hurwitz et al, 2004). Patients with ovarian cancer are prone
to bowel dysmotility and subacute bowel obstruction as a direct
result of the pathophysiology of the disease. These characteristics
may put ovarian cancer patients at a higher risk of having adverse
events like perforation with VEGF inhibition. The data from the
key phase II studies suggest that the risk of perforation is higher
for patients who were heavily pre-treated with chemotherapy
(more than three prior regimens). Although GOG-170D (Burger,
2007) did not report any cases of bowel perforation, eligible
patients were limited to two prior chemotherapy regimens. The
study of Cannistra et al (2007) was stopped early due to a
perforation rate of 11.4% (5 of 44 patients). All perforations
occurred in patients who had received three or more chemotherapy
regimens and there was a trend towards higher perforation rates in
patients with documented bowel wall involvement or bowel
obstruction at study entry. Bowel perforations and enteral fistulae
have also been reported in other phase II trials utilising bevacizumab
in advanced ovarian cancer (Azad et al, 2008; Garcia et al, 2008).
However, no definitive conclusions on aetiological factors can be
drawn, due to the small number of patients in each group. Data from
GOG-218 and ICON7 are awaited to clarify the risks of major
gastrointestinal complications in the first-line setting.
Reversible posterior leukoencephalopathy syndrome and tracheo-
oesophageal fistulae are significant, but rare, complications of
bevacizumab treatment. Vascular endothelial growth factor receptor
tyrosine kinase inhibitors have also been associated with clinical
hypothyroidism, which could be caused by the inhibition of iodine
uptake in the thyroid (Mannavola et al,2 0 0 7 ) .
METRONOMIC CHEMOTHERAPY AND VEGF
INHIBITORS
Tumour endothelium, by virtue of its higher proliferation rate
compared with the normal adult vasculature, makes itself a target
for anticancer treatment. Cytotoxic chemotherapy is convention-
ally administered at a dose close to its maximum-tolerated dose,
with breaks to allow the recovery of normal tissues. Chemotherapy
at this dose does kill proliferating vascular endothelial cells, but
recovery happens rapidly. In animal models, lower doses of
chemotherapy for example, paclitaxel, vinorelbine and cyclo-
phosphamide given frequently (metronomic dosing) target
proliferating endothelial cells leading to their apoptosis with few
side effects and no significant direct tumour cytotoxicity (Browder
et al, 2000; Hanahan et al, 2000; Klement et al, 2000). In ovarian
cancer, metronomic docetaxel chemotherapy in combination with
AEE788, a combined EGFR and VEGFR inhibitor, has shown
encouraging activity in an orthotopic mouse model utilising a cell
line resistant to conventional chemotherapy dosing (Kamat et al,
2007). This approach has also been explored in a phase II clinical
trial of bevacizumab (10mgkg
 1, every 2 weeks) and metronomic
oral cyclophosphamide (50mg daily) in platinum-resistant/par-
tially platinum-sensitive ovarian cancer with promising activity.
Median time to progression was 7.2 months and median survival
time was 16.9 months in this study involving 70 patients (Garcia
et al, 2008).
TARGETING ANGIOGENESIS THROUGH
ALTERNATIVE PATHWAYS
Although strategies directly inhibiting VEGF have shown clinical
activity and have confirmed angiogenesis inhibition as a
therapeutic anticancer option, not all cancers respond to this
approach and resistance inevitably develops in the clinical setting
presumably through the upregulation of alternative pro-angiogenic
pathways. Casanovas et al (2005) showed in an animal pancreatic
islet cell tumour model that evasion of VEGFR-2 signalling
blockade was achieved through the upregulation of FGF family
members. Interestingly, preliminary data from a phase II trial of
cediranib in glioblastoma indicated that circulating FGF-2
concentrations increased during drug holidays and on disease
progression, reinforcing the potential importance of this resistance
pathway (Batchelor et al, 2007). Several other resistance mechan-
isms have also been proposed including the recruitment of
vascular progenitor cells and monocytes from bone marrow as
well as the increased protection from better pericyte coverage
(Bergers and Hanahan, 2008). Recent animal evidences also
suggest that VEGFR-3 may have a role in driving angiogenic
sprouting in the presence of VEGFR-2 inhibitors, suggesting a role
for VEGF-C in mediating resistance to VEGFR-2 inhibition
(Tammela et al, 2008). The development of alternative/combina-
tion antiangiogenic approaches is therefore vitally important and
some of the more promising alternative targets are discussed below
(see Figure 1).
The epidermal growth factor receptor (EGFR) is overexpressed
in ovarian carcinoma, and EGFR signalling has been shown to
upregulate VEGF expression. Although erlotinib (EGFR tyrosine
kinase inhibitor) does not have any relevant single-agent activity
in ovarian cancer, combined VEGF and EGFR inhibition is
currently under investigation. The combination of erlotinib and
bevacizumab has already been explored in a phase II study
(Friberg et al, 2006), with two responses seen in 13 patients.
The platelet-derived growth factor (PDGF) signalling pathway is
another potential target for antiangiogenic therapy, as PDGFR
signalling is of key importance in maintaining the homoeostasis of
pericytes, mesenchymally derived cells that surround capillaries
and venules, and are vital for microvessel stability and function.
Platelet-derived growth factor and PDGFR have also been
identified in metastatic ovarian carcinoma, with overexpression
of PDGFR associated with poor prognosis (Dabrow et al, 1998).
Pre-clinical studies in ovarian cancer xenograft models have
shown increased efficacy for the combination of VEGFR and
PDGFR tyrosine kinase inhibitors associated with decreased vessel
coverage by pericytes supporting PDGF signalling as an anti-
angiogenic therapeutic target (Lu et al, 2007). However, ‘pure’
PDGFR inhibition needs to be approached with caution as a phase
II study of CDP860, a pegylated di-Fab’ molecule that binds to and
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because of significant toxicity due to fluid accumulation (Jayson
et al, 2005). Imaging studies demonstrated that CDP860 signifi-
cantly increased the ratio of vascular volume to tumour volume,
suggesting the recruitment of tumour-associated non-functioning
vessels.
Another pathway that is of emerging importance in tumour
angiogenesis is the Delta/Jagged-Notch system, which is involved
in cell–cell interaction in multicellular organisms, and is required
for the development of a normal cardiovascular system. The key
receptor–ligand pair in tumour endothelium appears to be delta-
like ligand-4 (DLL4) and Notch-1. Delta-like ligand-4 is normally
induced by VEGF as a negative-feedback regulator of vascular
growth and is strongly expressed in tumour vasculature. Delta-like
ligand-4 blockade in animal xenograft models interestingly results
in increased tumour vasculature but reduced tumour growth
(Thurston et al, 2007). The vessels formed in this way have
increased sprouting, with lack of maturation, and are too
disorganised to accommodate adequate perfusion. Further studies
need to be performed to delineate in detail the effects of DLL4
blockade on the normal vasculature, but it potentially represents a
very exciting therapeutic target.
Vascular endothelial growth factor gene expression is influenced
by several factors although hypoxia is vitally important. This leads
to the activation of hypoxia-inducible factor-1a, which activates
the transcription of multiple target genes including VEGF.
Hypoxia-inducible factor-1a levels are in turn controlled by
mammalian target of rapamycin (mTOR). Temsirolimus is an
inhibitor of mTOR and is currently under investigation in a phase
II study in recurrent ovarian cancer (GOG-0170I).
One of the key downstream mediators of VEGF signalling is the
protein kinase C (PKC) family of serine/threonine kinases.
Enzastaurin (LY317615) is an inhibitor of PKC-b that has shown
activity in phase I studies with minimal toxicity and is being
studied further in ovarian cancer (Carducci et al, 2006).
Volociximab (M200) is a monoclonal antibody that specifically
binds a5b1 integrin, which is part of a family of transmembrane
proteins that play a critical role in vasculogenesis (a5 integrins)
(Takada et al, 2007). Pre-clinical testing showed inhibition of
proliferating endothelial cells by volociximab and it is currently
under phase II investigation as a single agent in platinum-resistant
ovarian cancer.
FUTURE PROSPECTS AND CHALLENGES IN
ANTIANGIOGENIC TREATMENT
The pre-clinical and clinical studies show promise for the
antiangiogenic approach in ovarian cancer treatment. Many
unanswered questions, however, remain as to the best strategy to
use with these treatments. For instance, is combination with
chemotherapy the best approach and, if so, is concurrent
antiangiogenic therapy sufficient or should maintenance treatment
be pursued? Hopefully, answers to these questions will emerge for
bevacizumab from the ongoing phase III studies (ICON7 and
GOG-218). Given the plethora of antiangiogenic targets and drugs
under development, future research will also need to concentrate
on the best approaches to combine/sequence these agents.
Currently, one of the biggest challenges in the clinical
development of antiangiogenic agents is developing robust
biomarkers for clinical use that will allow us to both ascertain
the optimum biological dose of these agents in early clinical trials
and also to select those patients who are most likely to benefit from
antiangiogenic treatment. This is particularly important given the
costs and not the insignificant toxicity profiles of these agents.
Dynamic contrast-enhanced magnetic resonance imaging (DCE-
MRI) has been the most utilised pharmacodynamic imaging
modality in early phase clinical trials of angiogenic inhibitors. This
functional imaging technique is non-invasive and can be used to
serially assess tumour vasculature in vivo (O’Connor et al, 2007).
Although DCE-MRI evidence of drug-induced changes in the
intratumoral vasculature has guided dose selection in the phase I
setting, there is currently relatively little evidence that it can be
used to predict clinical benefit.
[
18F]fluorothymidine (FLT) PET imaging may be an early
metabolic predictor of response to antiangiogenic therapy. In a
phase II study of bevacizumab and irinotecan in recurrent
glioblastoma, patients whose tumours demonstrated a metabolic
response lived three times longer than non-responders (Chen et al,
2007), indicating that FLT-PET should be explored further.
Serological biomarkers for antiangiogenic treatment potentially
have greater clinical utility, given their lower cost and the ease of
repeated sampling compared with imaging strategies. Although
changes in the levels of circulating pro-angiogenic growth factors
in response to antiangiogenic drug exposure have been seen in
several early phase clinical trials and a pharmacodynamic signal
consistent with the inhibition of VEGFR-2 signalling (elevations in
VEGF-A and PlGF associated with falls in soluble VEGFR-2 and -3)
seems to be emerging from trials of VEGFR tyrosine kinase
inhibitors (Batchelor et al, 2007; Rini et al, 2008), no clear pattern
predictive of response or the subsequent development of treatment
resistance has emerged yet. The serial assessment of a panel of
circulating biomarkers is an integral part of the ICON7 trial, with
the aim of identifying markers of sensitivity to both antiangiogenic
therapy and early disease progression.
Circulating endothelial cell (CEC) and endothelial progenitor
cell (CEP) concentrations have also been shown to be promising
surrogate markers in pre-clinical studies (Shaked et al, 2005).
In the clinic, the benefit from metronomic chemotherapy in
metastatic breast cancer was associated with an elevation of CEC
levels secondary to apoptotic cells 2 months after the commence-
ment of the treatment (Mancuso et al, 2006). A subsequent study
by the same group has suggested that an elevated CEC level before
treatment commencement predicted clinical benefit from the
combination of metronomic chemotherapy and bevacizumab in
metastatic breast cancer (Dellapasqua et al, 2008). However,
although these results are intriguing, it should be noted that the
appropriate enumeration of CECs is technically challenging
(Strijbos et al, 2008). Interestingly, comparative data from four
phase II clinical trials of anti-VEGF agents presented at ASCO this
year in which an identical technology was used to measure CECs
indicated that changes in CEC/CEP levels did not demonstrate a
consistent pattern but were dependent on the antiangiogenic agent
used and the treatment context (Duda et al, 2008). Further studies
to identify clinically useful predictive and pharmacodynamic
biomarkers for angiogenesis and antiangiogenic therapy are
urgently needed.
CONCLUSIONS
Anti-VEGF drugs, in particular bevacizumab, have shown
promising activity as single agents in chemotherapy-resistant
ovarian cancer, supporting the strong pre-clinical rationale for the
utility of this treatment strategy. Combinations with chemotherapy
are currently being tested in clinical trials in the first-line setting
and it is hoped that this approach may significantly improve
patient outcome. Biomarkers of response, however, need to be
studied to enable a better selection of patients who will benefit
from treatment and to ascertain optimal dosing.
As more targets for antiangiogenic therapies emerge from
pre-clinical studies, the interactions between these different
pro-angiogenic pathways, the concept of combination antiangio-
genic treatments and the evaluation of mechanisms of ‘resistance’
to angiogenesis inhibitors will need to be addressed in the future.
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